Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Cyclosporine A for Primary Sjögren Syndrome
NCT01693393Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2010
- Primary completion
- Oct 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclosporine in primary Sjögren's syndrome, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Disease Activity Score 28 at 16 weeks, Number of tender joints at 16 weeks and 1 more. Started Mar 2010; status: completed.
02
Drugs
cyclosporine
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT01693393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01693393.